Musculoskeletal Metastasis From Soft-tissue Sarcomas: A Review of the Literature.
| Autor: | Pretell-Mazzini J; From the Musculoskeletal Oncology Division, Department of Orthopedics, Miller School of Medicine, University of Miami, Miami, FL (Pretell-Mazzini), University of Miami/Jackson Memorial Hospital Radiation Oncology Program, Miami, FL (Seldon), Department of Medicine, Sarcoma Medical Oncology, Sylvester Comprehensive Cancer Center, University of Miami (D'Amato), and the Department of Clinical Radiology and Orthopedic Surgery (Subhawong), and the Department of Radiology (Subhawong), Miller School of Medicine, University of Miami., Seldon CS, D'Amato G, Subhawong TK |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The Journal of the American Academy of Orthopaedic Surgeons [J Am Acad Orthop Surg] 2022 Jun 01; Vol. 30 (11), pp. 493-503. Date of Electronic Publication: 2022 Mar 22. |
| DOI: | 10.5435/JAAOS-D-21-00944 |
| Abstrakt: | Soft-tissue sarcomas are a rare and extremely heterogeneous group of cancers, representing <1% of all human malignancies. The lungs are the most common site of distant metastasis, followed by the bone, lymph nodes, liver, brain, and subcutaneous tissue. Clinical experience suggests that skeletal metastasis is part of the natural history affecting the prognosis and quality of life in these patients. Approximately 2.2% of patients have skeletal metastasis at diagnosis. However, up to 10% will develop skeletal metastasis after a mean interval of 21.3 months. Although systemic therapy with conventional chemotherapy remains the primary treatment modality for those with metastatic sarcoma, increased survival has been achieved in selected patients who receive multimodality therapy, including surgery, for their metastatic disease. The 5-year overall survival of patients with isolated bone metastases was 41.2% (26.9% to 54.9%), which decreased to 32.9% (21.2% to 45.1%) in the setting of combined bone and lung metastases. Moreover, the resection of the primary soft-tissue sarcoma is a predictor of survival, resulting in a 58% decrease in mortality after surgery (hazard ratio, 0.42, P = 0.013). Understanding the effect of these metastases on patient survival may influence imaging, surveillance, and treatment decisions. (Copyright © 2022 by the American Academy of Orthopaedic Surgeons.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|